Independent Coverage Disclosure: First Look Equities has received no compensation from Cardiol Therapeutics for this coverage. It is independent visibility content — not investment advice or a recommendation. We offer paid IR-visibility services to public companies, including companies we cover. Full disclosure
Quotes and filings for Cardiol Therapeutics open at their authoritative live sources. First Look Equities does not redistribute market data.
Cardiol Therapeutics (NASDAQ: CRDL).
First Look Equities has initiated corporate visibility coverage on Cardiol Therapeutics. We feature Cardiol as a clinical-stage biotechnology pioneer developing innovative, targeted anti-inflammatory therapies for cardiovascular disease. Their pipelines offer crucial cardioprotective clinical answers for high-performance leaders on land and at sea.
Key Identifiers
Progress in CardiolRx™ Clinical Trials.
Review Cardiol's current investigational treatments targeting inflammation in recurrent pericarditis and acute myocarditis.
Targeting debilitating pericardial inflammation.
Recurrent pericarditis is characterized by sharp chest pain and recurrent inflammation of the pericardial sac. It causes severe, life-altering morbidity.
Cardiol's MAVERIC-Pilot study reported positive top-line data in 2024, demonstrating significant, rapid reductions in pain (measured by Visual Analog Scale) and C-reactive protein (CRP), a key laboratory marker of systemic inflammation.
Clinical Takeaway
CardiolRx™ is designed to inhibit NLRP3 inflammasome activation, a key mediator in the development of cardiovascular inflammation. The positive trial results suggest CardiolRx™ represents a promising potential oral therapy for patients suffering from pericarditis pain.
- Reduction of pain severity scores
- Reduction of inflammation markers (CRP)
- Assessment of safety & tolerability profile
Clinical Milestones & Narrative Deck.
Review highlights from Cardiol Therapeutics' corporate presentation. This deck outlines the clinical development of CardiolRx™ in acute myocarditis and recurrent pericarditis.
Click through slide-by-slide or view them in sequence to see the clinical trials and data supporting Cardiol's anti-inflammatory therapeutic pipeline.
What an Initiated IR Package Looks Like.
Once a company engages First Look Equities to initiate visibility coverage, a structured set of deliverables goes live to establish a high-fidelity narrative footprint.
Upgrade to The Floating Roadshow
Companies under active coverage can upgrade their engagement at any time to include **The Uncharted Boardroom** Miami executive roadshow, hosting private target allocator presentations on the 102' Leopard yacht.
01. Research Initiation Page
A fully custom-scoped, optimized company coverage landing page (such as this) highlighting clinical trials, key catalysts, and corporate milestones in our Sovereign design system.
02. GEO & AI Search Audits
Systematic index optimization and structured dataset schemas to ensure LLM search engines (Perplexity, Gemini, ChatGPT) retrieve, summarize, and cite the company accurately.
03. Editorial Research Blog
Authoring of structured company features in our Insights hub (e.g., 'Health on the Water' profile) syndicated to target investor networks and active capital market channels.
04. Strategic Lead Funnel
Direct integration with our TimeBroker AI outreach tools to schedule 1-on-1 strategy calls with interested allocators, building a qualified meeting pipeline.
The Uncharted Boardroom: Connecting Executives on the Water.
First Look Equities coordinates exclusive private boardroom charters and strategic roadshow environments on our partner 102' Leopard yacht in Miami, Florida. We provide these facilities only for companies under active coverage.
Cardiol's executive team is eligible for the program, which organizes tarmac transit, white-glove Fontainebleau basecamp logistics, and presentation facilities to showcase clinical breakthroughs to qualified allocators.
MAVERIC Phase III clinical trial enrollment exceeded 75% for the pivotal study of oral CardiolRx™ in recurrent pericarditis.
Q1 2026 Form 6-K reports a cash position of $27.7M CAD supporting the clinical runway.
Phase II MAVERIC-Pilot data showed rapid, clinically meaningful reduction in pericarditis pain and inflammation markers.
Phase II ARCHER study is evaluating CardiolRx™ efficacy and safety in acute myocarditis.
Form 6-K: Q1 2026 Financial Statements and MD&A
Quarterly report outlining cash runway ($27.7M CAD), MAVERIC Phase III enrollment exceeding 75%, and Board recruitment updates.
View sourcePhase III MAVERIC Trial Recruitment Update
Recruitment exceeds 75% for the pivotal study evaluating the oral CardiolRx™ formulation in recurrent pericarditis.
View sourceTimeline entries summarize Cardiol Therapeutics's own public filings and press releases and link to the underlying source. First Look Equities does not verify, rate, or opine on these disclosures.
Want an investor page like Cardiol Therapeutics's — for your company?
First Look Equities × TimeBroker.ai build investor pages with an always-on AI IR representative that answers investor questions in real time — strictly from your public filings. Hosted here or built on your own site. A 30-second application starts your personalized demo.
Interested in Initiating Coverage?
IR firms and public issuers can request coverage or coordinate private boardrooms. Book a 15-minute discovery call to align on goals.
Book a Strategy Call